Anixa Biosciences, Inc.
ANIXHealthcare|Biotechnology|US
$3.17
+0.14 (+4.79%)
DCF Value
$0.03
Tangible Book / Share
$0.39
Cash / Share
$0.41
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05316129 Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer | Ovarian Cancer | P1 | Recruiting | 10 | Open-label | Follicle Stimulating Hormone Receptor T Cells |
| NCT04674306 Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Early P1 | Completed | 35 | Open-label | α-lactalbumin vaccine, Zymosan |